Eli Lilly trial update on kidney drug hurts Tectonic

Eli Lilly trial update on kidney drug hurts Tectonic

The pharmaceutical industry witnessed a notable development on September 22, 2023, as the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) 10 mg tablets for the treatment of adults with chronic kidney disease (CKD) at risk of progression [1]. This approval adds to the existing treatment options for the more than 35 million adults in the U.S. affected by CKD [1].

Jardiance's approval follows the results of the EMPA-KIDNEY phase III trial, which demonstrated that the SGLT2 inhibitor significantly reduced the risk of kidney disease progression and cardiovascular death in adults with CKD [1]. This trial is the first to establish a statistically significant reduction in the risk of first and recurrent hospitalization in adults with CKD [1].

The FDA's decision comes as a significant blow to Tectonic, a biopharmaceutical company that has been focusing on developing treatments for CKD. With Jardiance's approval, Tectonic faces increased competition in the market, potentially impacting its market share and revenue prospects.

The approval of Jardiance is not limited to its kidney benefits. It also reduces the risk of cardiovascular death and hospitalizations in adults with CKD [1]. This multifaceted approach sets Jardiance apart from other treatments currently available in the market, making it a valuable addition to the treatment options for healthcare professionals treating adults with CKD.

In conclusion, Eli Lilly's Jardiance approval marks a significant milestone in the treatment of CKD, providing healthcare professionals with another option to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalizations in adults with CKD. This development poses a challenge to Tectonic and other companies in the CKD market, necessitating a reevaluation of their strategies to maintain their market position.

References:
[1] Eli Lilly and Boehringer Ingelheim. (2023, September 22). US FDA approves Jardiance treatment for adults with chronic kidney disease. Retrieved from https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-jardiancer-treatment-adults-chronic-kidney